Clinics historically sold sermorelin and ipamorelin as interchangeable 'GH peptides', sometimes stacked. In 2026 the comparison has a sharp edge the menus don't advertise: the FDA's compounding review treated them completely differently. Here is the full comparison, receptor to courtroom.
The comparison table
| Sermorelin | Ipamorelin | |
|---|---|---|
| Mechanism | GHRH receptor (mimics the hypothalamic signal) | Ghrelin receptor (GHRP class, selective) |
| Feedback safety | Stays under somatostatin feedback | Also physiologic, pulse-shaped |
| Regulatory status | Formerly FDA-approved (Geref, 1997-2008); defensible compounding lane persists | Never approved; FDA Category 2, compounding blocked |
| Evidence in adults | Small, old studies; hormone effects documented, outcomes unproven | Pharmacology studies only; development abandoned by Novo Nordisk |
| Sport | WADA-prohibited | WADA-prohibited |
| Typical use pattern | Nightly mcg dosing | One to three mcg doses daily |
The difference that decides it in 2026
Pharmacologically these are complementary tools, which is why clinics stacked them. Legally they diverged completely: sermorelin's approval history keeps prescription compounding defensible in many states, while ipamorelin sits in Category 2 of the FDA's bulk-substances review, which removed its lawful compounding basis. A clinic offering sermorelin is operating a gray-but-arguable lane; a clinic offering ipamorelin is sourcing outside the sanctioned system, whatever the invoice says. For most people asking 'which one', the honest answer is that only one still has a lane at all.
What neither has
Controlled evidence that the GH elevation produces the sold outcomes: fat loss, muscle, sleep quality, or longevity in healthy adults. Both reliably move growth hormone and IGF-1; both stop at the hormone level evidentially. If outcomes are the requirement, tesamorelin (approved, with real visceral-fat trials) is the only member of this family that clears the bar, at a matching price.
Frequently asked questions
Which is better, sermorelin or ipamorelin?
Neither has outcome evidence, so 'better' reduces to practical facts: sermorelin has an approval history and a still-defensible compounding lane; ipamorelin is FDA Category 2 with no lawful route. On the only dimension with a clear answer, sermorelin wins by default.
Can you take sermorelin and ipamorelin together?
Clinics stacked them for years (GHRH plus ghrelin pathways do synergize pharmacologically), but the combination has no outcome trials, and the ipamorelin half of the stack has no legal supply basis since the Category 2 designation.
Do sermorelin or ipamorelin build muscle?
No controlled trial in healthy adults shows meaningful hypertrophy from either. They raise GH pulses; the muscle claim is inference. Our muscle-growth pillar covers what actually has evidence.